Julian Harrison
Stock Analyst at BTIG
(4.59)
# 238
Out of 5,111 analysts
69
Total ratings
62.9%
Success rate
21.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Reiterates: Buy | $5 | $1.61 | +210.56% | 3 | Dec 2, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $25 → $40 | $17.77 | +125.10% | 3 | Nov 26, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $32 → $38 | $10.82 | +251.20% | 2 | Nov 24, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $17 | $1.63 | +942.94% | 4 | Nov 20, 2025 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $42 → $44 | $8.97 | +390.52% | 2 | Nov 14, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $56 → $63 | $30.10 | +109.30% | 3 | Nov 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $2.30 | +334.78% | 2 | Nov 13, 2025 | |
| LQDA Liquidia | Reiterates: Buy | $49 | $34.19 | +43.32% | 4 | Nov 4, 2025 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $61 | $33.03 | +84.68% | 4 | Nov 4, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $82 | $94.79 | -13.49% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.81 | +109.97% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $4.22 | +255.45% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $76.81 | +49.72% | 2 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $15.25 | +83.61% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $120 | $117.91 | +1.77% | 3 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 | $14.32 | +493.58% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.70 | +125.99% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $53.30 | +87.62% | 1 | Sep 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $33.34 | +109.96% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $39.71 | -6.82% | 3 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.23 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $45.56 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $2.17 | +314.75% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.17 | +152.37% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.36 | +2,122.22% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.73 | +20,447.95% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $500.30 | - | 2 | Feb 11, 2022 |
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $5
Current: $1.61
Upside: +210.56%
Theravance Biopharma
Nov 26, 2025
Maintains: Buy
Price Target: $25 → $40
Current: $17.77
Upside: +125.10%
Cullinan Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $10.82
Upside: +251.20%
Rezolute
Nov 20, 2025
Reiterates: Buy
Price Target: $17
Current: $1.63
Upside: +942.94%
Cartesian Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $8.97
Upside: +390.52%
Oruka Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $56 → $63
Current: $30.10
Upside: +109.30%
Connect Biopharma Holdings
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.30
Upside: +334.78%
Liquidia
Nov 4, 2025
Reiterates: Buy
Price Target: $49
Current: $34.19
Upside: +43.32%
Viridian Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $33.03
Upside: +84.68%
Protagonist Therapeutics
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $94.79
Upside: -13.49%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $3.81
Upside: +109.97%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.22
Upside: +255.45%
Oct 9, 2025
Reiterates: Buy
Price Target: $115
Current: $76.81
Upside: +49.72%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $15.25
Upside: +83.61%
Oct 7, 2025
Maintains: Buy
Price Target: $112 → $120
Current: $117.91
Upside: +1.77%
Sep 29, 2025
Downgrades: Neutral
Price Target: $85
Current: $14.32
Upside: +493.58%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $17.70
Upside: +125.99%
Sep 19, 2025
Reiterates: Buy
Price Target: $100
Current: $53.30
Upside: +87.62%
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $33.34
Upside: +109.96%
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $39.71
Upside: -6.82%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $21.23
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $45.56
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $2.17
Upside: +314.75%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.17
Upside: +152.37%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.36
Upside: +2,122.22%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.73
Upside: +20,447.95%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $500.30
Upside: -